These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3008320)

  • 1. Acute myelogenous leukemia of unfavourable prognosis treated with retinoic acid, vitamin D3, alpha-interferon and low doses of cytosine arabinoside.
    Robèrt KH; Hellström E; Einhorn S; Gahrton G
    Scand J Haematol Suppl; 1986; 44():61-74. PubMed ID: 3008320
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of refractory undifferentiated acute myelogenous leukemia with all-trans-retinoic acid.
    Griggs JJ; Henley SE; Rowe JM
    Am J Hematol; 1994 Feb; 45(2):177-80. PubMed ID: 8141124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases.
    Huang ME; Ye YC; Chen SR; Zhao JC; Gu LJ; Cai JR; Zhao L; Xie JX; Shen ZX; Wang ZY
    Chin Med J (Engl); 1987 Dec; 100(12):949-53. PubMed ID: 3133168
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of acute promyelocytic leukemia by retinoic acid with or without low dose cytosine arabinoside: report of 4 cases].
    Huang ME; Ye YC; Zhao L
    Zhonghua Nei Ke Za Zhi; 1987 Jun; 26(6):330-2, 380. PubMed ID: 3477416
    [No Abstract]   [Full Text] [Related]  

  • 5. [Aplastic anemia which terminated in hypoplastic leukemia 10 years after diagnosis].
    Nishii K; Katayama N; Komada F; Kageyama S; Hoshino K; Tsukada T; Nishikawa M; Kobayashi T; Minami N; Shirakawa S
    Rinsho Ketsueki; 1990 Sep; 31(9):1523-6. PubMed ID: 2174086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating agents in the treatment of leukemia.
    Degos L
    Leuk Res; 1990; 14(8):717-9. PubMed ID: 2201823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
    Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
    Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukaemic cells.
    Hassan HT; Rees JK
    Hematol Oncol; 1988; 6(1):39-45. PubMed ID: 3422632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia.
    Roberts JD; Ershler WB; Tindle BH; Stewart JA
    Cancer; 1985 Sep; 56(5):1001-5. PubMed ID: 3860278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating agents in the treatment of leukemia and myelodysplastic syndromes.
    Degos L
    Leuk Res; 1990; 14(8):731-3. PubMed ID: 2201824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of recurrent acute myelogenous leukaemia at a single centre over a 10-year period.
    Davis CL; Rohatiner AZ; Amess J; Lim J; Lister TA
    Haematol Blood Transfus; 1990; 33():339-41. PubMed ID: 2323639
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
    Estey EH; Kantarjian HM; Beran M; McCredie KB; Keating MJ; Deisseroth A; Gutterman JU
    Haematol Blood Transfus; 1990; 33():732-6. PubMed ID: 2182463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response of acute non-lymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
    Peters WG; Willemze R; Colly LP; Colla L
    Br J Haematol; 1985 Apr; 59(4):733-4. PubMed ID: 3857074
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of early acute nonlymphatic leukemia with low dose cytosine arabinoside.
    Moloney WC; Rosenthal DS
    Haematol Blood Transfus; 1981; 26():59-62. PubMed ID: 7033074
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside and alpha-interferon on bone marrow cells from patients with myelodysplastic syndromes.
    Hellström E; Robèrt KH; Soppi E; Ost A; Putkonen PO; Gahrton G
    Leuk Res; 1989; 13(12):1113-21. PubMed ID: 2615468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cytosine arabinoside in the initial treatment of acute leukemia.
    Barnett MJ; Waxman JH; Richards MA; Ganesan TS; Bragman KS; Rohatiner AZ; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):133-8. PubMed ID: 3859927
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin 2.
    Butturini A; Bonilauri E; Izzi G; Croci G; Franchi F; Santucci MA; Tondelli MT; Castriota Scanderbeg A
    Leuk Res; 1991; 15(8):759-63. PubMed ID: 1910127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine.
    Recent Results Cancer Res; 1973; 43():165-8. PubMed ID: 4531077
    [No Abstract]   [Full Text] [Related]  

  • 19. [Abnormalities of the erythropoiesis at the beginning of remission in acute promyelocytic leukemia treated with arabinoside-cytosine].
    Dubois-Ferrière H; Aguercif M; Hazeghi P; Rudhardt M
    Schweiz Med Wochenschr; 1970 Feb; 100(7):321-3. PubMed ID: 5263342
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.